Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 436-710-6 | CAS number: 756-13-8
CAS 756-13-8 had an LD50 Oral greater than 2000 mg/kg bw, an LD50 Dermal greater than 2000 mg/kg bw and an LC50 Inhalation greater than 98658 ppmThe Oral LD50 is greater than 2000 mg/kg and weight gain during the study period was considered normal. The Dermal LD50 is greater than 2000 mg/kg and weight gain during study period was considered normal. The Inhalation LC50 is greater than 98,658 ppm. There were no deaths. Treatment related exaggerated breathing was seen during the test period and in the first two hours after the test period. Breathing was normal in days 2-14 of the observation period. Weight gain was normal during the study period.Cardiac Sensitization was evaluated in beagle dogs with the addition of adrenaline up to an air concentration of 15.4%. No signs of cardiac sensitization, which was determined by EKG monitoring, was seen in this test. The material is not a cardiac sensitizer up to 15.4%.In the Eye Irritation/Corrosion study, slight conjunctival irritation was seen in one animal. This was completely resolved within 24 hours. No other signs of irritation were noted and the material is not considered to be an eye irritant.In the Primary Skin Irritation study, no irritation was noted in any animal at any time point and the material is not considered to be a skin irritant.A Buehler sensitization study was conducted. No skin reactions were seen in the challenge phase of the study and the material is not considered to be a sensitizer.
CAS 756-13-8 was administered by oral gavage at 2000 mg/kg bw according to OECD 423. No mortality was observed. Weight gain during the study period was considered normal.
CAS 756-13-8 was administered dermally at 2000 mg/kg bw according to OECD 402. No mortality was observed and weight gain during study period was considered normal. Lethargy, hunched posture and/or other symptoms were observed in most animals but these resolved by day 4 in all but one animal.
Animals were exposed to a concentration of 98,658 ppm of CAS 756-13-8. No mortality was observed. Treatment related exaggerated breathing was seen during the test period and in the first two hours after the test period. Breathing was normal in days 2-14 of the observation period. Weight gain was normal during the study period.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again